Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PGYJL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IPH43
|
|||||
| Synonyms |
IPH-43; IPH 43
Click to Show/Hide
|
|||||
| Organization |
Innate Pharma SA; AstraZeneca PLC
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Glycosylated Anti-MICA Anti-ody
|
Antibody Info | ||||
| Antigen Name |
MHC class I polypeptide-related sequence A (MICA)
|
Antigen Info | ||||
| Payload Name |
PBD dimer
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation through the glutamine 295 by an engineered transglutaminase (mTgase).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.